Abstract:Systemic sclerosis (SSc) is a progressive, multi-organ disease with limited treatment options. While a recent proof-of-concept study using Romilkimab or SAR156597, a bi-specific IL-4/IL-13 antibody, suggests a direct role of these cytokines in the pathophysiology of SSc, their contributions to the balance between inflammation and fibrosis are unclear. Here, we determine the roles of type 2 inflammation in fibrogenesis using a Fos-related antigen 2 overexpressing transgenic mice (FRA2-Tg), which develop a spontaneous, age-dependent progressive lung fibrosis. We defined the molecular signatures of inflammation and fibrosis at three key stages in disease-progression, corresponding to pre-onset, inflammatory dominant, and fibrosis dominant biology, and revealed an early increase in cytokine-cytokine receptor interactions and antigen-processing and presentation pathways followed by enhanced Th2 and M2- macrophage driven type 2 responses. This type-2 inflammation progressed to extensive fibrotic pathology by 14-18 weeks of age with these gene signatures overlapping significantly with those seen in lungs of patients with SSc with interstitial lung disease (ILD). These changes were also evident in the histopathology which showed perivascular and peribronchiolar inflammation with prominent eosinophilia and accumulation of profibrotic M2-like macrophages followed by rapid progression to fibrosis with thickened alveolar walls with multifocal-fibrotic-bands and signs of interstitial-pneumonia. Critically, treatment with a bispecific antibody targeting IL-4 and IL-13 during the inflammatory phase abrogated the Th2 and M2-responses and led to near complete abrogation of lung fibrosis. These data recapitulate important features of fibrotic-progression in lungs of SSc-ILD patients and enhance our understanding of the progressive pathobiology of SSc. This study also further establishes FRA2-Tg mice as a valuable tool for testing future therapeutic agents in SSc-ILD.

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Phenotypes and Serum Biomarkers in Sarcoidosis

Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?

High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities

Recent advances in sarcoidosis

Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis

Cystic lung in sarcoidosis: Clinico‐radiologic characteristic and evolution

Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis

Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword

The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis

Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach

Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2

Imaging of Pulmonary Sarcoidosis—A Review

Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation

Pleural involvements in pulmonary sarcoidosis: A case report and review of the literature

Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis

Infectious Complications of Pulmonary Sarcoidosis

Progress of Biological Markers in Sarcoidosis Diagnosis

Research progress on relationship between sarcoidosis and infection

Clinical management of pulmonary sarcoidosis

Predicting the risk of pulmonary deterioration in sarcoidosis